Started from a PhD thesis in the University of Sydney, we are building a generational medical technology company right here in Australia. Today marks the beginning of an exciting new chapter as we list on ASX. This IPO is not the end of our journey; it is the beginning of our growth phase. We built a culture of urgency and excellence and now we invite you to be a part of our future.
The Tetratherix-BioOptix collaboration aims to disrupt the status quo by launching the first dedicated, custom-engineered ophthalmic viscoelastic device (OVD) specifically designed for use in the eye. Tetramatrix™ platform technology will enable a step-change in the performance and biocompatibility of the current OVDs, due to its unique physical properties leading to improvements in patients’ and clinicians’ experience in intraocular procedures.
A homegrown biotechnology story that has been 15 years in the making, built on its co-founder Dr Ali Fathi’s ambition to create regenerative medicine that supports the body’s own healing processes, is entering a new phase as Tetratherix aims for a $25 million ASX listing at the end of this month.
Already backed by Radar Ventures’ Atlanta Daniel and Rod Drury, the founder of Xero (ASX: XRO), the company has completed multiple trials of its patented Tetramatrix and is targeting the markets of bone regeneration, tissue spacing and tissue healing.
Tetratherix, a medical device company backed by Xero founder Rod Drury, is set to float on the ASX this month, raising $25 million with an ambitious pitch to investors about the potential of its “medical Lego” product that helps the human body heal faster from injuries and surgery.
The company’s product has been in scientific development since 2011, and is built on the work of chief technical officer Ali Fathi, a biomolecular engineer who invented a new material that can be injected into wounds to help tissue and bones heal.
A Novel Approach Using Thermoresponsive Polymers
The research behind our polymer platform continues to compound, now focusing on the intranasal delivery of peptide/proteins like GLP-1, insulin and other therapeutic proteins.
What does that mean? A non-invasive, patient-friendly route to deliver powerful therapies that were once limited by needles, enzymatic degradation, or poor absorption. It’s not just a technical achievement — it’s a leap toward redefining how we treat metabolic disease, neurodegeneration, and beyond.
A recently published study has demonstrated the power of our polymer platform in enhancing bone repair, showing real promise for faster, stronger healing. This isn’t just an incremental improvement — it’s a step-change in how we think about supporting the body’s regenerative potential.
At Tetratherix, we’re not in the business of tweaking what’s already been done. We’re here to build what should exist. This data pushes us — and the field — toward a future where bone healing is met with precision materials that guide, not just patch, biological recovery.
The science is catching up to the vision. And we’re just getting started.
